| HOME >> BIOLOGY >> TECHNOLOGY |
Jason Rando (media)
(646) 536-7025
NeurogesX, Inc.
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
Three Months Ended March 31,
2008 2007
Operating expenses:
Research and development(1) $5,781 $6,196
General and administrative(2) 2,487 1,653
Total operating expenses 8,268 7,849
Loss from operations (8,268) (7,849)
Interest income 504 203
Interest expense (243) (332)
Other income 17 59
Net loss (7,990) (7,919)
Accretion of redeemable convertible
preferred stock - (3,437)
Loss attributable to common stockholders $(7,990) $(11,356)
Net loss per common share - basic and diluted:
Loss per share attributable to
common stockholders $(0.46) $(17.25)
Shares used to compute basic and
diluted loss per share attributable
to common stockholders 17,468,395 658,364
Non-cash stock-based compensation expense
included in operating expenses:
(1) Research and development
'/>"/>
| SOURCE NeurogesX, Inc. Copyright©2008 PR Newswire. All rights reserved |